达芙蓉片治疗痔疮及缓解症状的研究

IF 0.3 Q4 PHARMACOLOGY & PHARMACY
Leila Hajimaghsoudi, Mojtaba Ahmadinejad, Mohsen Karimian, Mohammad Hadi Bahri, Ali Karbalaeikhani, Izadmehr Ahmadinejad
{"title":"达芙蓉片治疗痔疮及缓解症状的研究","authors":"Leila Hajimaghsoudi, Mojtaba Ahmadinejad, Mohsen Karimian, Mohammad Hadi Bahri, Ali Karbalaeikhani, Izadmehr Ahmadinejad","doi":"10.2174/0115748855260887230925095817","DOIUrl":null,"url":null,"abstract":"Background: Varicose-like bulging veins that occur in the anus and lower rectum are known as hemorrhoids. Depending on their degree of prolapse, they can cause symptoms such as bleeding, discomfort, mucous discharge, perianal irritation, and burning. The aim of the study was to investigate the impact of Daflon pills on the treatment of hemorrhoids and their associated symptoms, as well as the duration of hospitalization and the likelihood of recurrence. Methods: A randomized clinical trial was used in this investigation. Patients who had been referred to the surgical clinic of the Madani Hospital in 2021 with hemorrhoid complaints were participants in a random selection process. Participants were separated into control groups (getting non-invasive regular treatments) and the intervention group after being informed and given ethical approval (Receiving Daflon 500 mg twice daily for 4 weeks). Patients' symptoms, potential sequelae, and illness recurrence were assessed in both chosen groups at each visit, and data was gathered until the desired sample size was reached. Results: This study was performed on 200 patients who received Daflon 500 mg (intervention, N = 100) or placebo (control, N = 100). The number of visits required to achieve therapeutic goals did not differ statistically significantly between the intervention and control groups (P >0.05). The mean recovery time was 56.5 ± 12.53 days for the intervention group and 61.04 ± 13.63 days for the control group, which is considered statistically significant (P<0.05). A total of 56 patients (28.0%) relapsed and 144 patients (72.0%) recovered. This rate in the intervention group included 78 (78.0%) recovery and 22 (22.0%) relapsed and in the control group 66 (66.0%) recovered and 34 (34.0%) relapsed, clinically it suggests that treatment Daflon can prevent relapse of the disease, although the statistical results of this study do not support this hypothesis (P = 0.059). Conclusion: The study's findings demonstrated that Daflon therapy is a superior and more effective treatment option for all grades of hemorrhoids. Moreover, the medication's side effects are manageable, making it a well-tolerated choice.","PeriodicalId":11004,"journal":{"name":"Current Drug Therapy","volume":"41 1","pages":"0"},"PeriodicalIF":0.3000,"publicationDate":"2023-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Use of Daflon Tablets in Treating Hemorrhoids and Alleviating Symptoms\",\"authors\":\"Leila Hajimaghsoudi, Mojtaba Ahmadinejad, Mohsen Karimian, Mohammad Hadi Bahri, Ali Karbalaeikhani, Izadmehr Ahmadinejad\",\"doi\":\"10.2174/0115748855260887230925095817\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Varicose-like bulging veins that occur in the anus and lower rectum are known as hemorrhoids. Depending on their degree of prolapse, they can cause symptoms such as bleeding, discomfort, mucous discharge, perianal irritation, and burning. The aim of the study was to investigate the impact of Daflon pills on the treatment of hemorrhoids and their associated symptoms, as well as the duration of hospitalization and the likelihood of recurrence. Methods: A randomized clinical trial was used in this investigation. Patients who had been referred to the surgical clinic of the Madani Hospital in 2021 with hemorrhoid complaints were participants in a random selection process. Participants were separated into control groups (getting non-invasive regular treatments) and the intervention group after being informed and given ethical approval (Receiving Daflon 500 mg twice daily for 4 weeks). Patients' symptoms, potential sequelae, and illness recurrence were assessed in both chosen groups at each visit, and data was gathered until the desired sample size was reached. Results: This study was performed on 200 patients who received Daflon 500 mg (intervention, N = 100) or placebo (control, N = 100). The number of visits required to achieve therapeutic goals did not differ statistically significantly between the intervention and control groups (P >0.05). The mean recovery time was 56.5 ± 12.53 days for the intervention group and 61.04 ± 13.63 days for the control group, which is considered statistically significant (P<0.05). A total of 56 patients (28.0%) relapsed and 144 patients (72.0%) recovered. This rate in the intervention group included 78 (78.0%) recovery and 22 (22.0%) relapsed and in the control group 66 (66.0%) recovered and 34 (34.0%) relapsed, clinically it suggests that treatment Daflon can prevent relapse of the disease, although the statistical results of this study do not support this hypothesis (P = 0.059). Conclusion: The study's findings demonstrated that Daflon therapy is a superior and more effective treatment option for all grades of hemorrhoids. Moreover, the medication's side effects are manageable, making it a well-tolerated choice.\",\"PeriodicalId\":11004,\"journal\":{\"name\":\"Current Drug Therapy\",\"volume\":\"41 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2023-10-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Drug Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/0115748855260887230925095817\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Drug Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115748855260887230925095817","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

背景:出现在肛门和直肠下部的静脉曲张样膨出的静脉称为痔疮。根据脱垂程度的不同,它们会引起出血、不适、粘液排出、肛周刺激和灼烧等症状。该研究的目的是调查达芙蓉丸对痔疮治疗及其相关症状的影响,以及住院时间和复发的可能性。方法:采用随机临床试验。2021年因痔疮就诊于马达尼医院外科诊所的患者参加了随机选择过程。参与者被分为对照组(接受非侵入性常规治疗)和干预组,在被告知并获得伦理批准后(接受达芙蓉500毫克,每天两次,持续4周)。每次访问时,对两组患者的症状、潜在的后遗症和疾病复发进行评估,并收集数据,直到达到所需的样本量。结果:本研究对200例患者进行了研究,这些患者接受了达芙蓉500 mg(干预,N = 100)或安慰剂(对照组,N = 100)。达到治疗目标所需的就诊次数在干预组和对照组之间无统计学差异(P >0.05)。干预组平均恢复时间为56.5±12.53 d,对照组平均恢复时间为61.04±13.63 d,差异有统计学意义(P<0.05)。复发56例(28.0%),恢复144例(72.0%)。干预组恢复78例(78.0%),复发22例(22.0%),对照组恢复66例(66.0%),复发34例(34.0%),临床提示使用Daflon治疗可预防疾病复发,但本研究统计结果不支持这一假设(P = 0.059)。结论:本研究结果表明,达芙蓉治疗是所有级别痔疮的优越和更有效的治疗选择。此外,这种药物的副作用是可控的,使其成为一种耐受性良好的选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The Use of Daflon Tablets in Treating Hemorrhoids and Alleviating Symptoms
Background: Varicose-like bulging veins that occur in the anus and lower rectum are known as hemorrhoids. Depending on their degree of prolapse, they can cause symptoms such as bleeding, discomfort, mucous discharge, perianal irritation, and burning. The aim of the study was to investigate the impact of Daflon pills on the treatment of hemorrhoids and their associated symptoms, as well as the duration of hospitalization and the likelihood of recurrence. Methods: A randomized clinical trial was used in this investigation. Patients who had been referred to the surgical clinic of the Madani Hospital in 2021 with hemorrhoid complaints were participants in a random selection process. Participants were separated into control groups (getting non-invasive regular treatments) and the intervention group after being informed and given ethical approval (Receiving Daflon 500 mg twice daily for 4 weeks). Patients' symptoms, potential sequelae, and illness recurrence were assessed in both chosen groups at each visit, and data was gathered until the desired sample size was reached. Results: This study was performed on 200 patients who received Daflon 500 mg (intervention, N = 100) or placebo (control, N = 100). The number of visits required to achieve therapeutic goals did not differ statistically significantly between the intervention and control groups (P >0.05). The mean recovery time was 56.5 ± 12.53 days for the intervention group and 61.04 ± 13.63 days for the control group, which is considered statistically significant (P<0.05). A total of 56 patients (28.0%) relapsed and 144 patients (72.0%) recovered. This rate in the intervention group included 78 (78.0%) recovery and 22 (22.0%) relapsed and in the control group 66 (66.0%) recovered and 34 (34.0%) relapsed, clinically it suggests that treatment Daflon can prevent relapse of the disease, although the statistical results of this study do not support this hypothesis (P = 0.059). Conclusion: The study's findings demonstrated that Daflon therapy is a superior and more effective treatment option for all grades of hemorrhoids. Moreover, the medication's side effects are manageable, making it a well-tolerated choice.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current Drug Therapy
Current Drug Therapy PHARMACOLOGY & PHARMACY-
CiteScore
1.30
自引率
0.00%
发文量
50
期刊介绍: Current Drug Therapy publishes frontier reviews of high quality on all the latest advances in drug therapy covering: new and existing drugs, therapies and medical devices. The journal is essential reading for all researchers and clinicians involved in drug therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信